With the new acquisition, Cliantha Research will have the capabilities to perform Phase I, II, III and IV clinical research in North America
Cliantha Research has announced the acquisition of Inflamax Research. Inflamax has locations in Toronto, ON; Neptune, NJ and Newark, NJ. Cliantha Research will have the capabilities to perform Phase I, II, III and IV clinical research in North America. Inflamax’s expertise in inflammatory disease research and patented natural allergen Environmental Exposure Chambers (EEC) shall allow Cliantha to conduct Asthma, Allergy, Ophthalmology, Tobacco research plus specialised pulmonary/ respiratory therapeutic studies.
The two New Jersey clinics were acquired by Hill Top Research (St. Petersburg, FL), a wholly owned subsidiary of Cliantha Research since 2011. With two clinical sites in the US, Hill Top Research can conduct HRIPT studies as per FDA guidance.
"Inflamax is the leader in research in inflammatory disease with a specialty in Environmental Exposure Chamber technologies. Now we can provide our sponsors with advanced clinical trial designs along with a strong, highly experienced scientific team in North America. This acquisition brings us closer to our goal of offering highly specialised trials to our sponsor." said Vijay Patel, Executive Director, Cliantha Research.
Dr Piyush Patel, CEO of Inflamax Research, commented, "I am very excited about the future prospects of Inflamax Research and the Cliantha team working together. This merger brings together the best of our collective scientific research capabilities and expands our infrastructure and offerings to our clients. There are many synergies between Inflamax Research and Cliantha which will offer new and expanded opportunities to our clients."
The Inflamax Toronto Clinic and Chambers will continue to operate under the current leadership of Dr Piyush Patel and Dr Anne Marie Salapatek as Inflamax Research. The New Jersey Clinical units will be integrated with the US operation as Hill Top Research to offer world-class dermatology research studies such as HRIPT, Adhesion, Cumulative Irritation and PK studies.
The experimental vaccine against SARS-CoV-2 that was the first to enter human trials in the United States has been shown to elicit neutralizing antibodies and a helpful T-cell response with the aid of a carefully engineered spike protein that mimics ...